Relugolix/estradiol/norethisterone acetate
Combination medication From Wikipedia, the free encyclopedia
Relugolix/estradiol/norethisterone acetate, sold under the brand names Myfembree and Ryeqo, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and for moderate to severe pain associated with endometriosis.[8][9][10] It contains relugolix, an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol, an estrogen, and norethisterone acetate, a progestin.[8][9] The medication is taken by mouth.[8]
 | |
| Combination of | |
|---|---|
| Relugolix | GnRH antagonist |
| Estradiol (medication) | Estrogen |
| Norethisterone acetate | Progestogen |
| Clinical data | |
| Trade names | Myfembree, Ryeqo |
| Other names | RGX/E2/NETA; MVT-601 |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a622069 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The most common side effects of the medication include hot flushes, excessive sweating or night sweats, uterine bleeding, hair loss or thinning, and decreased interest in sex.[8]
The medication was approved for medical use in the United States in May 2021,[8][11][12] and in the European Union in July 2021.[9]
Medical uses
The medication is used in the treatment of heavy menstrual bleeding associated with uterine fibroids and for moderate to severe pain associated with endometriosis, both in premenopausal women.[8][10]
Available forms
The medication is formulated as an oral tablet containing a fixed-dose combination of 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate.[8]
Pharmacology
Pharmacodynamics
Relugolix acts as an GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor.[13] Estradiol is an estrogen, or an agonist of the estrogen receptors, whereas norethisterone acetate is a progestin (synthetic progestogen), or an agonist of the progesterone receptors.[14] Relugolix suppresses ovarian sex hormone production, whereas estradiol and norethisterone acetate provide hormonal add-back to reduce hypogonadal and menopausal-like symptoms.[13]
History
The medication was approved for medical use in the United States in May 2021.[8][11]
In May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ryeqo, intended for the treatment of symptoms of uterine fibroids.[15] The applicant for this medicinal product is Gedeon Richter Plc.[15] The combination was approved for medical use in the European Union in July 2021.[9][16]
In August 2022, the medication was approved for the treatment of moderate to severe pain associated with endometriosis in the United States.[10]
Research
The combination is also under development as a birth control pill for prevention of pregnancy in premenopausal women.[17]
References
Further reading
Wikiwand - on
Seamless Wikipedia browsing. On steroids.